19 research outputs found
AML IN REMISSION, ORIGINATING FROM MDS-RARS-T, EXPANDS THE UNDERLYING JAK2 V617F MUTATED CLONE
Get PDFA mutation in the JAK2 gene is commonly found in patients with MPN, which can sometimes lead to secondary AML. In this case study, we are reporting on an interesting case of secondary AML originating from MDS-RARS-T. The patient had no gross chromosomal changes, and we found that he was JAK2 V617F-mutated. His BM showed 53% of myeloid blasts. After the induction of combined therapy of Venetoclax and Azacytidine, a complete remission of the disease was achieved. However, instead of the expected decrease in the mutated JAK2 alleles, we documented a rise from the initial 55% to 79% of mutated alleles. This can be explained by the fact that treatment for AML targets only one subclone
Angiotensin I-converting enzyme is expressed by erythropoietic cells of normal and myeloproliferative bone marrow
No full textTelomere length shortening is associated with disease evolution in chronic myelogenous leukemia
Full text linkAssessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis
No full textHigher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis
No full textCombining information on C reactive protein and serum albumin into the Glasgow Prognostic Score strongly discriminates survival of myelofibrosis patients
No full textLoss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia
No full text
